Eric Nagaonlé Somé*, Issaka Zongo, Félicité Nana, Daouda Sané, Maxime Drabo, Roger Sombié
Abstract: In Burkina Faso, the prevalence of HBs antigen is estimated at 9.1%. We aimed to describe the therapeutic and evolutionary aspects of chronic HBeAg-negative viral hepatitis B outpatients at the University Hospital Yalgado Ouédraogo. Methods: It was a cross-sectional descriptive study including 325 participants with a retrospective data collection from January 2004 to April 2016. Results: The mean age was 38.7 years and the sex ratio, 1.5. The mean concentration of HBsAg and HBV Viral load was 7861.6 IU/mL and 32 237.20 IU/mL, respectively. A total of 84 participants were on antiviral therapy; 73 (86.9%) and six (7.1%) patients were on tenofovir and lamivudine, respectively. Under tenofovir, the virological response was complete and ALT was normal in 44.4% and 77.7% of the patients after one year. HBV DNA was undetectable and ALT normal under Lamivudine in 50% of the patients after four years. The adherence to the treatment was high, moderate or low in 71.4%, 21.4% and 7.2% of the cases, respectively. In high adherent group, HBV DNA was undetectable and ALT normal in 91.6% and 95% of cases, respectively. Under tenofovir and lamivudine, we noted an HBsAg seroconversion after 2 and seven years of treatment, respectively. CONCLUSION: The prevalence of chronic HBeAg negative hepatitis B patients is currently increasing. The HBs seroconversion is still low. The sensitization of the population to avoid the viral hepatitis infection mainly by a systematic immunization of the population remains the most effective weapon to fight this disease.[...] Read More.
Keywords: hepatitis B infection, HBs antigen, HBe antigen, antiviral treatment, adherence, sub Saharan Africa.
